Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 78Tumor-Agnostic 8Breast 6Thoracic 5Gastrointestinal 5CNS 4Head & Neck 3Sarcoma 2Other solid neoplasm 2Gynecologic 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Endocrine 1Classical hematology 1

Conditions

Ovarian Neoplasms 2Recurrence 1

Interventions

Paclitaxel 581Carboplatin 528Cisplatin 359Bevacizumab 256pembrolizumab 228Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 128Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 91niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 74Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 57Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
cabazitaxel × Gynecologic × Clear all
NCT02560337 2020-10-08

CaTo-ROC

Vejle Hospital

Phase 2 Completed
26 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT01747239 2014-12-04

Cabazitaxel in Platinum Refractory Ovarian Cancer

Vejle Hospital

Phase 2 Terminated
4 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡